XML 56 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Note 10 - Stock-based Compensation
3 Months Ended
Sep. 30, 2019
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]
10.
Stock-Based Compensation
 
On
September
 
15,
2010,
the Company’s Board of Directors (the “Board”) adopted the Contango ORE, Inc. Equity Compensation Plan (the
“2010
Plan”).
On
November 14, 2017,
the Stockholders of the Company approved and adopted the Contango ORE, Inc. Amended and Restated
2010
Equity Compensation Plan (the “Amended Equity Plan”). The amendments to the
2010
Plan included (a) increasing the number of shares of Common Stock that the Company
may
issue under the plan by
500,000
shares; (b) extending the term of the plan until
September 15, 2027;
and (c) allowing the Company to withhold shares to satisfy the Company
’s tax withholding obligations with respect to grants paid in Company Stock.
Under the Amended Equity Plan, the Board
may
issue up to
1,500,000
shares of common stock and options to officers, directors, employees or consultants of the Company. Awards made under the Amended Equity Plan are subject to such restrictions, terms and conditions, including forfeitures, if any, as
may
be determined by the Board. As of 
September 30, 2019,
there were
456,666
shares of unvested restricted common stock outstanding and
zero
options to purchase shares of common stock outstanding issued under the Amended Equity Plan. Stock-based compensation expense for the
three
 months ended 
September 30, 2019
was
$740,442
.
Stock-based compensation expense for the
three
 months ended September
30,
2018
 
was
$745,069
. 
The amount of compensation expense recognized does
not
reflect cash compensation actually received by the individuals during the current period, but rather represents the amount of expense recognized by the Company in accordance with GAAP.  All restricted stock grants are expensed over the applicable vesting period based on the fair value at the date the stock is granted.  The grant date fair value
may 
differ from the fair value on the date the individual’s restricted stock actually vests.
 
Restricted Stock.
 In 
November 2017,
the Company granted
155,000
restricted shares of common stock to its executives and non-executive directors. The restricted stock granted vests in
January 2020.
As of 
September 30, 2019,
there were
155,000
shares of such restricted stock that remained unvested.
 
In 
November 2018,
the Company granted
155,000
restricted shares of common stock to its executives and non-executive directors. The restricted stock granted vests in
January 2021.
As of 
September 30, 2019,
there were
155,000
shares of such restricted stock that remained unvested.
 
In
December 2018,
the Company cancelled
117,332
shares of unvested restricted stock held by
two
of its executives and the non-executive directors that were set to vest on
January 1, 2019. 
The Company also granted
146,666
restricted shares of common stock to
two
of its executives and non-executive directors. The restricted shares cancellation and the subsequent new grants were accounted for as modification to the original restricted stock grants.  The incremental fair value will be recognized over the vesting period.  The impact of the modification to the current quarter was immaterial.  All of the restricted stock granted in
December 2018
vest in
January 2021. 
As of 
September 30, 2019,
there were
146,666
shares of such restricted stock that remained unvested.
 
  
As of 
September 30, 2019
, the total compensation cost related to unvested awards
not
yet recognized was
$2,272,268.
The remaining costs will be recognized over the remaining vesting period of the awards.  Neither Brad Juneau, 
the Company’s Chairman, President and Chief Executive Officer, nor any of the Company’s non-executive directors have ever been paid a salary or cash compensation by the Company.
 
   
There were
no
stock option exercises during the quarter ended
September 30, 2019
.  
During the quarter ended
September 30, 2018
the Company's current and former executives, directors, and consultants cashless exercised
35,625
stock options resulting in the issuance of
19,513
shares of common stock to the exercising parties and
no
proceeds to the Compa
ny.  The Company applies the fair value method to account for stock option expense. Under this method, cash flows from the exercise of stock options resulting from tax benefits in excess of recognized cumulative compensation cost (excess
tax benefits) are classified as financing cash flows. See Note
3
– Summary of Significant Accounting Policies. All employee stock option grants are expensed over the stock option’s vesting period based on the fair value at the date the options are granted. The fair value of each option is estimated as of the date of grant using the Black-Scholes options-pricing model. As of 
September 30, 2019, there were no stock options outstanding
. The total compensation cost related to these options has been fully recognized as all of the options are fully vested.